News

GKT831 recorded high statistical significance following six weeks of treatment, said the French biotech company. The 24-week placebo-controlled trial is being held across multiple countries in 111 PBC

IPI-549 is an oral immuno-oncology development candidate, which is designed to selectively inhibit phosphoinositide-3-kinase (PI3K)-gamma. It is claimed to be the only investigational PI3K-gamma inhibitor in clinical development.

The program’s investment has tripled the site’s GMP capacity, added new equipment for solid oral dose manufacturing and significantly increased staffing levels. Quotient Sciences CEO Mark Egerton said:

Lorbrena is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) to treat patients with ALK-positive metastatic NSCLC whose disease has progressed on crizotinib and at least

The ORTHO-NOVUM product itself remains safe and effective for use with the appropriate dispenser instructions.  Women should continue to take the 21 “active” pills (with hormones) (peach for

The acquisition adds to the company’s growing pipeline with the addition of clinical-stage SYNT001, a humanized monoclonal antibody that inhibits the interaction of neonatal Fc receptor (FcRn) with

EPIDIOLEX, which was approved by the U.S. Food and Drug Administration (FDA) on June 25, 2018, is the first prescription pharmaceutical formulation of highly purified, plant-derived cannabidiol (CBD),

A total of 79 patients with COPD have enrolled at sites in the U.S. and in the UK in this three way crossover study. It is anticipated that

The approval allows more patients to be treated with Venclyxto in the second-line setting while giving healthcare providers the ability to prescribe the drug to a larger population